Evidence map›Paper›PMID 40093096›Full record

ArticlebioRxiv : the preprint server for biology2025

The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies.

Marta Krawczyk, Narcis Fernandez-Fuentes, Klaudyna Fidyt, Tomasz Winiarski, Monika Pepek, Agnieszka Graczyk-Jarzynka, Jacinta Davis, Pablo Bousquets-Muñoz, Xose S Puente, Pablo Menendez and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marta KrawczykDepartment of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
Narcis Fernandez-FuentesJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Klaudyna FidytDepartment of Immunology, Medical University of Warsaw, Warsaw, Poland.
Tomasz WiniarskiWarsaw University of Technology, Institute of Control and Computation Engineering, Warsaw, Poland.
Monika PepekDepartment of Immunology, Medical University of Warsaw, Warsaw, Poland.
Agnieszka Graczyk-JarzynkaDepartment of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
Jacinta DavisDivision of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Pablo Bousquets-MuñozDepartamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.
Xose S PuenteDepartamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.
Pablo MenendezJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Emmanuelle BenardTranslational Research Unit, Section of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Sébastien WälchliTranslational Research Unit, Section of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Andrei Thomas-TikhonenkoDivision of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-2739-2206
Magdalena WiniarskaDepartment of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.

Funding

RED CELL HEMOGLOBIN RESEARCH TRAINING PROGRAMT32HL007150 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI STELLA T CHOU, Mortimer Poncz · 1985 to 2026
$7.4M
NHLBI NIH HHS T32 HL007150
6 · The paper itself

Abstract

CD19-CAR-T-cells emerge as a major therapeutic option for relapsed/refractory B-cell-derived malignancies, however approximately half of patients eventually relapse. To identify resistance-driving factors, we repeatedly exposed B-cell lymphoma/B-cell acute lymphoblastic leukemia to 4-1BB/CD28-based CD19-CAR-T-cells

Identifiers

PMID40093096
PMCPMC11908201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.